Answers are grounded in this paper and cite their sources.
Our early-phase data showed that administration of ipilimumab was feasible in patients with recurrent hematologic cancers after allogeneic HSCT, although immune-mediated toxic effects and GVHD occurred. Durable responses were observed in association with several histologic subtypes of these cancers, including extramedullary acute myeloid leukemia. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT01822509.).
No takes yet. Share an insight, caveat, or question.
Davids et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: